東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Novel anticancer drug delivery syste...

Pakunlu, Refika Isil.

FindBook

Google Book

Amazon

博客來

Novel anticancer drug delivery system for molecular targeting of pump and nonpump cellular resistance.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Novel anticancer drug delivery system for molecular targeting of pump and nonpump cellular resistance./
作者:	Pakunlu, Refika Isil.
面頁冊數:	171 p.
附註:	Adviser: Tamara Minko.
Contained By:	Dissertation Abstracts International68-02B.
標題:	Health Sciences, Oncology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3253012

Novel anticancer drug delivery system for molecular targeting of pump and nonpump cellular resistance.
Pakunlu, Refika Isil.

Novel anticancer drug delivery system for molecular targeting of pump and nonpump cellular resistance. - 171 p.

Adviser: Tamara Minko.

Thesis (Ph.D.)--Rutgers The State University of New Jersey - New Brunswick, 2007.

The efficacy of cancer chemotherapy is limited by the development of cancer cell resistance. This resistance depends on two main components (1) pump resistance and (2) nonpump resistance. Pump resistance depends on special cellular membrane proteins which pump out an anticancer drug, decreasing the drug concentration inside cancer cells. A special family of antiapoptotic proteins plays a key role in nonpump cancer resistance limiting the cell death, which is induced by the drug. Chemotherapy simultaneously activates pump and nonpump cancer resistance, necessitating progressive increase in drug dosage, which in turn induces significant adverse side effects. To enhance the efficacy of cancer treatment, we are proposing a novel drug delivery system, which includes (1) an inducer of cell death - an anticancer drug, (2) a suppressor of pump resistance and (3) inhibitor of nonpump resistance, (4) liposomes as carriers. It is expected that this system will significantly enhance the efficacy of cancer treatment. Experimental results show that PEGylated liposomes are capable of penetrating directly into tumor cells after systemic administration in vivo and do successfully provide cytoplasmic and nuclear delivery of encapsulated anticancer drug (doxorubicin, DOX) and antisense oligonucleotides (ASO). Encapsulation of DOX and ASO into liposomes substantially increased their specific activity. Simultaneous suppression of pump and nonpump resistance dramatically enhanced the ability of DOX for inducing apoptosis leading to higher in vitro cytotoxicity and in vivo antitumor activity.Subjects--Topical Terms:

1018566
Health Sciences, Oncology.

Novel anticancer drug delivery system for molecular targeting of pump and nonpump cellular resistance.
LDR:02503nam 2200265 a 45 001 964145
005 20110901
008 110901s2007 eng d
035 $a (UMI)AAI3253012
035 $a AAI3253012
040 $a UMI $c UMI
100 1 $a Pakunlu, Refika Isil. $3 1287214
245 1 0 $a Novel anticancer drug delivery system for molecular targeting of pump and nonpump cellular resistance.
300 $a 171 p.
500 $a Adviser: Tamara Minko.
500 $a Source: Dissertation Abstracts International, Volume: 68-02, Section: B, page: 0912.
502 $a Thesis (Ph.D.)--Rutgers The State University of New Jersey - New Brunswick, 2007.
520 $a The efficacy of cancer chemotherapy is limited by the development of cancer cell resistance. This resistance depends on two main components (1) pump resistance and (2) nonpump resistance. Pump resistance depends on special cellular membrane proteins which pump out an anticancer drug, decreasing the drug concentration inside cancer cells. A special family of antiapoptotic proteins plays a key role in nonpump cancer resistance limiting the cell death, which is induced by the drug. Chemotherapy simultaneously activates pump and nonpump cancer resistance, necessitating progressive increase in drug dosage, which in turn induces significant adverse side effects. To enhance the efficacy of cancer treatment, we are proposing a novel drug delivery system, which includes (1) an inducer of cell death - an anticancer drug, (2) a suppressor of pump resistance and (3) inhibitor of nonpump resistance, (4) liposomes as carriers. It is expected that this system will significantly enhance the efficacy of cancer treatment. Experimental results show that PEGylated liposomes are capable of penetrating directly into tumor cells after systemic administration in vivo and do successfully provide cytoplasmic and nuclear delivery of encapsulated anticancer drug (doxorubicin, DOX) and antisense oligonucleotides (ASO). Encapsulation of DOX and ASO into liposomes substantially increased their specific activity. Simultaneous suppression of pump and nonpump resistance dramatically enhanced the ability of DOX for inducing apoptosis leading to higher in vitro cytotoxicity and in vivo antitumor activity.
590 $a School code: 0190.
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0572
690 $a 0992
710 2 0 $a Rutgers The State University of New Jersey - New Brunswick. $3 1017590
773 0 $t Dissertation Abstracts International $g 68-02B.
790 $a 0190
790 1 0 $a Minko, Tamara, $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3253012